The bill, called “The Prescription Drug Pricing Reduction Act of 2019,” addresses drug costs in Medicare Parts B and D, as well as Medicaid. The provisions affecting Medicare Part D include setting a cap on out-of-pocket spending and incentivizing more price negotiations between plans and drug manufacturers. To Part B, the bill would update calculation formulas for prescription drug payments to benefit patients, and in Medicaid, it would increase price transparency and extend benefits to cover gene therapies for rare diseases, among other provisions.
The Congressional Budget Office estimates the bill could save taxpayers approximately $100 billion, reduce out-of-pocket costs by $27 billion and deliver $5 billion in savings on premiums.
The Senate Finance Committee plans to mark up the bill July 25. House Democrats are also working on a bill to lower drug prices, which they plan to introduce after the Congressional recess.
More articles on leadership and management:
California health system to lay off 43 employees
4 Democratic presidential candidates back Kaiser workers in strike
Seema Verma is ‘deeply concerned’ about ‘Medicare for All,’ public option
At Becker's 4th Annual CEO + CFO Roundtable, taking place November 2–5 in Chicago, more than 1,500 hospital and health system executives tackle decisions that determine whether organizations thrive or merely survive: protecting margins under cost pressure, choosing where to grow, renegotiating payer relationships, stabilizing the workforce and proving real ROI on technology. This is where leaders work through them together, face-to-face. Apply for complimentary registration now.